1GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.
2Souery, D, Serretti, A, Calati, R, Oswald, P, Massat, I, Konstantinidis, A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 2011; 31: 512–6.
3Tansey, KE, Guipponi, M, Hu, X, Domenici, E, Lewis, G, Malafosse, A, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679–82.
4Fabbri, C, Corponi, F, Souery, D, Kasper, S, Montgomery, S, Zohar, J, et al. The genetics of treatment-resistant depression: a critical review and future perspectives. Int J Neuropsychopharmacol 2018; April 21 (Epub ahead of print).
5American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, revised) (DSM-IV-TR). APA, 2000.
6Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22–33
7Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
8Dold, M, Bartova, L, Mendlewicz, J, Souery, D, Serretti, A, Porcelli, S, et al. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatr Scand 2018; 137: 401–12.
9American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV). APA, 1994.
10Trivedi, MH, Rush, AJ, Ibrahim, HM, Carmody, TJ, Biggs, MM, Suppes, T, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73–82.
11Rush, AJ, Fava, M, Wisniewski, SR, Lavori, PW, Trivedi, MH, Sackeim, HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119–42.
12World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
13Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
14 Iniesta, R, Malki, K, Maier, W, Rietschel, M, Mors, O, Hauser, J, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res 2016; 78: 94–102.
15Souery, D, Oswald, P, Massat, I, Bailer, U, Bollen, J, Demyttenaere, K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007; 68: 1062–70.
16Fabbri, C, Tansey, KE, Perlis, RH, Hauser, J, Henigsberg, N, Maier, W, et al. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics J 2017; 18: 413–21.
17Patterson, N, Price, AL, Reich, D. Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.
18Li, Y, Willer, CJ, Ding, J, Scheet, P, Abecasis, GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34: 816–34.
19Dudbridge, F, Gusnanto, A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008; 32: 227–34.
20Watanabe, K, Taskesen, E, van Bochoven, A, Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun 2017; 8: 1826.
21de Leeuw, CA, Mooij, JM, Heskes, T, Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol 2015; 11: e1004219.
22Ionita-Laza, I, Lee, S, Makarov, V, Buxbaum, JD, Lin, X. Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet 2013; 92: 841–53.
23Chen, JJ, Roberson, PK, Schell, MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control J Moffitt Cancer Cent 2010; 17: 58–62.
24Anderson, GR, Galfin, T, Xu, W, Aoto, J, Malenka, RC, Südhof, TC. Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proc Natl Acad Sci U S A 2012; 109: 18120–5.
25Xu, C, Mullersman, JE, Wang, L, Bin Su, B, Mao, C, Posada, Y, et al. Polymorphisms in seizure 6-like gene are associated with bipolar disorder I: evidence of gene × gender interaction. J Affect Disord 2013; 145: 95–9.
26Maccarrone, G, Ditzen, C, Yassouridis, A, Rewerts, C, Uhr, M, Uhlen, M, et al. Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. J Psychiatr Res 2013; 47: 1572–80.
27Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371–9.
28Antypa, N, Drago, A, Serretti, A. Genomewide interaction and enrichment analysis on antidepressant response. Psychol Med 2014; 44: 753–65.
29Cai, S, Huang, S, Hao, W. New hypothesis and treatment targets of depression: an integrated view of key findings. Neurosci Bull 2015; 31: 61–74.
30Tardito, D, Perez, J, Tiraboschi, E, Musazzi, L, Racagni, G, Popoli, M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 2006; 58: 115–34.
31Duman, RS, Malberg, J, Nakagawa, S, D'Sa, C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732–9.
32Hufgard, JR, Williams, MT, Skelton, MR, Grubisha, O, Ferreira, FM, Sanger, H, et al. Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a. Psychopharmacology (Berl) 2017; 234: 1803–13.
33Jurek, B, Slattery, DA, Hiraoka, Y, Liu, Y, Nishimori, K, Aguilera, G, et al. Oxytocin regulates stress-induced Crf gene transcription through CREB-regulated transcription coactivator 3. J Neurosci 2015; 35: 12248–60.
34Tsankova, NM, Berton, O, Renthal, W, Kumar, A, Neve, RL, Nestler, EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519–25.
35Lin, H, Geng, X, Dang, W, Wu, B, Dai, Z, Li, Y, et al. Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res 2012; 1447: 119–25.
36Erburu, M, Muñoz-Cobo, I, Diaz-Perdigon, T, Mellini, P, Suzuki, T, Puerta, E, et al. SIRT2 inhibition modulate glutamate and serotonin systems in the prefrontal cortex and induces antidepressant-like action. Neuropharmacology 2017; 117: 195–208.